Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: Inactivation of the NF-κB pathway and generation of reactive oxygen species

Cancer Research

Volumn 70, Issue 6, 2010, Pages 2516-2527

  Jin, Yanli ^a   Lu, Zhongzheng ^a   Ding, Ke ^b   Li, Juan ^c   Du, Xin ^d   Chen, Chun ^c   Sun, Xiaoyong ^a   Wu, Yongbin ^a   Zhou, Jing ^b   Pan, Jingxuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTHELMINTIC AGENT; ANTIINFECTIVE AGENT; CYTARABINE; DAUNORUBICIN; DNA; ETOPOSIDE; GLUTATHIONE; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICLOSAMIDE; REACTIVE OXYGEN METABOLITE; SYNAPTOTAGMIN I; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CANCER INHIBITION; CONTROLLED STUDY; DNA BINDING; DNA TRANSCRIPTION; DRUG EFFECT; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GENE CONTROL; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRECURSOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEM CELL;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA, NEOPLASM; DRUG SYNERGISM; GENES, REPORTER; HL-60 CELLS; HUMANS; I-KAPPA B PROTEINS; LEUKEMIA, MYELOID, ACUTE; MALE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED BALB C; NEOPLASTIC STEM CELLS; NF-KAPPA B; NICLOSAMIDE; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 77950212486     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3950     Document Type: Article

References (37)

1. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol 2009;37:649-658
2. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a smallmolecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
3. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567-6571
4. Hewamana S, Alghazal S, Lin TT, et al. The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008;111:4681-4689
5. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-436
6. Chen F, Castranova V. Nuclear factor-κB, an unappreciated tumor suppressor. Cancer Res 2007;67:11093-11098
7. Jost PJ, Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007;109: 2700-2707
8. Frelin C, Imbert V, Griessinger E, et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005;105:804-811
9. Carvalho G, Fabre C, Braun T, et al. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2007;26:2299-2307
10. Jenkins C, Hewamana S, Gilkes A, et al. Nuclear factor-κB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. Br J Haematol 2008;143:661-671
11. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001;98:2301-2307
12. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007;110:4427-4435
13. Griessinger E, Imbert V, Lagadec P, et al. AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells. Leukemia 2007;21:877-885
14. Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003;278:37832-37839
15. Jin Y, Chen Q, Shi X, et al. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci 2009;100:1335-1343
16. Shi X, Jin Y, Cheng C, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009;15:1686-1697
17. Pan J, Quintas-Cardama A, Kantarjian HM, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007;109:315-322
18. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB-regulated gene products and TAK1-mediated NF-κB activation. Blood 2007;109:2727-2735
19. Ma C, Ying C, Yuan Z, et al. dp5/HRK is a c-Jun target gene and required for apoptosis induced by potassium deprivation in cerebellar granule neurons. J Biol Chem 2007;282:30901-30909
20. Shambharkar PB, Blonska M, Pappu BP, et al. Phosphorylation and ubiquitination of the IκB kinase complex by two distinct signaling pathways. EMBO J 2007;26:1794-1805
21. Blonska M, Shambharkar PB, Kobayashi M, et al. TAK1 is recruited to the tumor necrosis factor-á (TNF-á) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-κB activation. J Biol Chem 2005;280:43056-43063
22. Kang MI, Henrich CJ, Bokesch HR, et al. A selective small-molecule nuclear factor-κB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits". Mol Cancer Ther 2009;8:571-581
23. Pan J, She M, Xu ZX, Sun L, Yeung SC. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 2005;65:3671-3681
24. Pan J, Quintas-Cardama A, Manshouri T, et al. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-α-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia 2007;21:1395-1404
25. + blood stem cells derived from a single donor. Cell Prolif 2006;39:325-332
26. Sakurai H, Miyoshi H, Toriumi W, Sugita T. Functional interactions of transforming growth factor β-activated kinase 1 with IκB kinases to stimulate NF-κB activation. J Biol Chem 1999;274:10641-10648
27. Romashkova JA, Makarov SS. NF-κB is a target of AKT in antiapoptotic PDGF signalling. Nature 1999;401:86-90.
28. Weinbach EC, Garbus J. Mechanism of action of reagents that uncouple oxidative phosphorylation. Nature 1969;221:1016-1018
29. + transhydrogenation by adult Hymenolepis diminuta mitochondria. Parasitol Res 2006;98:200-206
30. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579-591
31. Groeger G, Quiney C, Cotter TG. Hydrogen peroxide as a cell survival signaling molecule. Antioxid Redox Signal 2009;11:2655-2671
32. Bubici C, Papa S, Dean K, Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-κB: molecular basis and biological significance. Oncogene 2006;25:6731-6748
33. Merschjohann K, Steverding D. In vitro trypanocidal activity of the anti-helminthic drug niclosamide. Exp Parasitol 2008;118: 637-640
34. Mercer-Haines N, Fioravanti CF. Hymenolepis diminuta: mitochondrial transhydrogenase as an additional site for anaerobic phosphorylation. Exp Parasitol 2008;119:24-29
35. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E. Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004;18:103-112
36. Tsimberidou AM, Estey E, Wen S, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008;113:1605-1613
37. Wang AM, Ku HH, Liang YC, Chen YC, Hwu YM, Yeh TS. The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells. J Cell Biochem 2009;106:682-692